Evidence map›Paper›PMID 24670084›Full record

ArticleThe Journal of clinical endocrinology and metabolism2014

Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD.

Martin Kaufmann, J Christopher Gallagher, Munro Peacock, Karl-Peter Schlingmann, Martin Konrad, Hector F DeLuca, Rita Sigueiro, Borja Lopez, Antonio Mourino, Miguel Maestro and 4 more

Open access · bronzeAbstract readEvaluation Study
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed, 2 pooled it
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

102 citing papers in PubMed, 2 syntheses or guidelines pooled it, 244 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Trial
  4. Trial
  5. Trial
  6. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  7. Trial
  8. Vitamin D binding protein rs7041 genotype alters vitamin D metabolism in pregnant women.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2018
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Significance of Fibroblast Growth Factor 23 and 24,25-Dihydroxyvitamin D in Dent Disease Type 1.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  18. 25-Hydroxyvitamin DCommunications medicine · 2026
    Article
  19. Review
  20. Article

42 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 9 institutions in 5 countries.

Martin KaufmannDepartment of Biomedical and Molecular Sciences (M.Ka., G.J.), Queen's University, Kingston, Ontario, Canada K7L 3N6; Bone Metabolism Unit (J.C.G.), Creighton University School of Medicine, Omaha, Nebraska 68131; Indiana University School of Medicine (M.P.), Indianapolis, Indiana 46202-5250; Department of General Pediatrics, (K-P. S., M.Ko.) University Children's Hospital, D-48149, Münster, Germany; Department of Biochemistry (H.F.D.), University of Wisconsin-Madison, Madison, Wisconsin 53706; Departmento de Quimica Organica (R.S., B.L., A.M., M.M.), Laboratorio Ignacio Ribas, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain; McGill University and Shriners Hospital for Children-Canada (R.S.), Montréal, Québec, Canada H3G 1A6; Endocrine Unit (J.S.F.), Massachusetts General Hospital, Boston Massachusetts 02114; and Health Sciences Research, Waters Corporation (D.P.C), Stamford Avenue, Altrincham Rd, Wilmslow, SK9 4AX United Kingdom.
J Christopher Gallagher
Munro Peacock
Karl-Peter Schlingmann
Martin Konrad
Hector F DeLuca
Rita Sigueiro
Borja Lopez
Antonio Mourino
Miguel Maestro
René St-Arnaud
Joel S Finkelstein
Donald P Cooper
Glenville Jones
Queen's University · CAUniversidade de Santiago de Compostela · ESUniversity Hospital Münster · DECreighton University · USIndiana University – Purdue University Indianapolis · USMassachusetts General Hospital · USMcGill University · CAUniversity of Wisconsin–Madison · USWaters (United Kingdom) · GB

Funding

INDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0M
Determination of RDA for Vitamin D in Caucasian and African American WomenR01AG028168 · NIA · CREIGHTON UNIVERSITY · PI GALLAGHER, JOHN CHRISTOPHER · 2006 to 2009
$1.9M
NCRR NIH HHS UL1 RR025761NCRR NIH HHS UL1RR025761NIA NIH HHS R01 AG028168NIA NIH HHS R01-AG28168
6 · The paper itself

Abstract

contextThe discovery of hypercalcemic diseases due to loss-of-function mutations in 25-hydroxyvitamin D-24-hydroxylase has placed a new demand for sensitive and precise assays for 24,25-dihydroxyvitamin D [24,25-(OH)2D].

objectiveWe describe a novel liquid chromatography and tandem mass spectrometry-based method involving derivatization with DMEQ-TAD {4-[2-(6,7-dimethoxy-4-methyl-3,4-dihydroquinoxalinyl)ethyl]-1,2,4-triazoline-3,5-dione} to simultaneously assay multiple vitamin D metabolites including 25-hydroxyvitamin D (25-OH-D) and 24,25-(OH)2D using 100 μL of serum with a 5-minute run time.

designThe assay uses a newly synthesized internal standard d6-24,25-(OH)2D3 enabling the quantitation of 24,25-(OH)2D3 as well as the determination of the ratio of 25-OH-D3 to 24,25-(OH)2D3, a physiologically useful parameter.

settingWe report data on more than 1000 normal and disease samples involving vitamin D deficiency or hypercalcemia in addition to studies involving knockout mouse models.

resultsThe assay showed good correlation with samples from quality assurance schemes for 25-OH-D (25-OH-D2 and 25-OH-D3) determination (-2% to -5% bias) and exhibited low inter- and intraassay coefficients of variation (4%-7%) and lower limits of quantitation of 0.25-0.45 nmol/L. In clinical studies, we found a strong correlation between serum levels of 25-OH-D3 and 24,25-(OH)2D3 (r(2) = 0.80) in subjects over a broad range of 25-OH-D3 values and a marked lack of production of 24,25-(OH)2D3 below 25 nmol/L of 25-OH-D. The ratio of 25-OH-D3 to 24,25-(OH)2D3, which remained less than 25 in vitamin D-sufficient subjects (serum 25-OH-D < 50 nmol/L) but was greatly elevated (80-100) in patients with idiopathic infantile hypercalcemia.

conclusionsThe new method showed good utility in clinical settings involving vitamin D deficiency; supplementation with vitamin D and idiopathic infantile hypercalcemia, as well as in animal models with ablation of selected cytochrome P450-containing enzymes involved in vitamin D metabolism.

Indexed as

24,25-Dihydroxyvitamin D 3AnimalsBlood Chemical AnalysisChromatography, LiquidDietary SupplementsFemaleHumansHypercalcemiaMiceMice, KnockoutPredictive Value of TestsQuinoxalinesTandem Mass SpectrometryTriazolesVitamin DVitamin D Deficiency24,25-Dihydroxyvitamin D 325-hydroxyvitamin D4-(2-(6,7-dimethoxy-4-methyl-3-oxo-3,4-dihydroquinoxalinyl)ethyl)-1,2,4-triazoline-3,5-dioneQuinoxalinesTriazolesVitamin D

Identifiers

PMID24670084
PMCPMC4079315
OpenAlexW2041302995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.